The significant improvement in PFS and DOR resulted in FDA approval of amivantamab and lazertinib as first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutation in 2024 [54]. Here, EGFR is linked to non-small cell lung carcinoma.